Singapore, Oct. 16 -- Sumitomo Pharma and Novo Nordisk Pharma have entered into a co-promotion agreement in Japan for Wegovy(R) Subcutaneous Injection, a once-weekly subcutaneous injection formulation of GLP-1 receptor agonist indicated for the treatment of obesity disease.

Wegovy(R) has been marketed since 22 February 2024 by Novo Nordisk Pharma in Japan. Under this agreement, Novo Nordisk Pharma will be responsible for maintenance of the marketing approval as well as manufacture and supply of the product, and Novo Nordisk Pharma and Sumitomo Pharma will be jointly committed to promoting the product to healthcare professionals. The co-promotion activities by both companies will begin in November 2025.

Novo Nordisk Pharma is supporting ...